Developer docs
API playgroundTry for free, no card

Search company profiles

NOTA Labs

Full company profile

uuid0002rjx

Namestring
NOTA Labs
Legal namestring
NOTA Laboratories
Websiteurl
notalabs.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

NOTA Laboratories (doing business as NOTA Labs) is a University of Michigan spinout founded in 2014 and headquartered in Ann Arbor, Michigan. The company is a development-stage medical device firm focused on proprietary nitric oxide (NO) delivery systems that leverage NO's antiviral, antimicrobial, anti-inflammatory, anti-thrombotic, and vasodilatory properties. Products are explicitly for investigational use only and not available for commercial sale, with no disclosed revenue to date.

The company's core technology rests on two patented platform systems. NOGEN is an electrochemical system that generates high-volume nitric oxide (up to 500 ppm) continuously for up to 6 months by reducing nitrite, regulated by varying current and voltage with multi-sensor in-line controls; it targets hospital use cases including persistent pulmonary hypertension in newborns (PPHN), open-heart surgery (thrombosis and SIRS prevention), lung transplantation, and ECMO. LANOR is a UV-LED photochemical system that converts a solid NO donor molecule via light energy using a proprietary film cassette, producing a compact, lightweight, battery-operated device intended for home and ambulatory use, particularly for COPD patients. A catheter lock solution rounds out the pipeline. Single-use disposable NO technologies have been separated into a spinout, NOxygen Therapeutics.

NOTA's anticipated business model is hardware sales of the NOGEN and LANOR systems plus recurring consumable revenue from chemical cartridges and film cassettes, though no pricing has been disclosed. GTM is multi-modal: enterprise field sales targeting hospital systems for NOGEN, sales-led development partnerships with medical device distributors (notably the NGK/CAIRE joint development agreement for bundled oxygen-concentrator-plus-NO distribution into the COPD market), and a future direct-to-consumer motion for LANOR in home care. Capital structure includes a $4.3 million NIH SBIR grant and a second venture round led by Pegasus Tech Ventures.

Short descriptiontext

NOTA Labs is a University of Michigan spinout developing proprietary nitric oxide delivery systems (NOGEN electrochemical platform and LANOR UV-LED platform) plus a catheter lock solution for hospital, ambulatory, and home-care applications. Pre-commercial, investigational-use only.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAnn Arbor, United States
HQ citystring
Ann Arbor
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nitric oxide delivery, medical device platforms, inhaled nitric oxide therapy, catheter lock solutions, respiratory therapy devices
Industry4 codes
PRIMARYHLAHAGAD
Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHANAF
Personal Protective Equipment (PPE) (Gloves, Masks/Respirators, Gowns, Face Shields)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Nitric Oxide Delivery Medical Devices
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Hardware Sales
TypeHardware Sales
Description

Pre-commercial development stage. Revenue anticipated from sale of NO generation systems (NOGEN and LANOR) along with associated disposable components (chemical cartridges, film cassettes). Products under development for FDA approval.

prnewswire.com
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NOTA Labs develops proprietary nitric oxide (NO) delivery platform technologies for therapeutic applications in respiratory, inflammatory, infectious, cardiovascular, and catheter-related conditions. The portfolio includes the NOGEN electrochemical system for high-volume hospital use, the LANOR UV-LED photochemical system for compact home/ambulatory use, and an NO-releasing intravascular catheter lock solution for infection and thrombosis prevention. All products are currently for investigational use only and not commercially available.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • NOGEN generates up to 500 ppm NO, compared to traditional tank-based systems costing $100/hour
+1 more record
Product overview1 text field

NOTA Labs offers a portfolio of nitric oxide (NO) delivery systems comprising two platform technologies: the NOGEN System (electrochemical NO generation for hospital/high-volume applications) and the LANOR System (UV-LED photochemical NO generation for home/ambulatory use), along with a catheter lock solution for preventing catheter-related infections. All products leverage NO's antiviral, antimicrobial, anti-thrombotic, anti-inflammatory, and vasodilatory properties.

Product and service3 records
1NOGEN System
CategoryNitric Oxide Delivery Medical Devices
Description

Electrochemical nitric oxide generation system that produces up to 500 ppm NO continuously for up to 6 months using inexpensive chemical cartridges; designed for hospital use in PPHN, open heart surgery (prevention of thrombosis and SIRS), lung transplantation, and ECMO/extracorporeal circulation applications. Products are for investigational use only and not commercially available.

2LANOR System
CategoryNitric Oxide Delivery Medical Devices
Description

UV-LED based photochemical nitric oxide generation system that converts a solid NO donor molecule from a film cassette using light energy; compact, lightweight, and battery-operated, enabling home/ambulatory use for COPD, chronic respiratory infections, and emergency applications. Products are for investigational use only and not commercially available.

3Catheter Lock Solution
CategoryCatheter Infection Prevention Solutions
Description

Novel nitric oxide-releasing intravascular (IV) catheter lock solution that delivers NO inside catheter walls to prevent microbial growth and clotting, reducing risk of catheter-related bloodstream infection (CRBSI) and catheter thrombosis for healthcare facilities.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1NGK Spark Plugs (Nagoya, Japan)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-28
Description

NOTA signed a Joint Development Agreement with NGK Spark Plugs for development and manufacturing collaboration. NGK owns CAIRE Inc., a major supplier of oxygen concentrators for home, clinic, and hospital use. The collaboration aims to integrate NOTA's NO systems with CAIRE oxygen concentrators to provide broader solutions for COPD patients, potentially reducing exacerbations and improving quality of life. NGK brings expertise in design, engineering, and manufacturing to accelerate products to market.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NOTA is a University of Michigan spinout company founded in 2014. The LANOR system was developed in collaboration with the University of Michigan. Dr. Mark Meyerhoff, the company's founder and chairman, leads research at the University's Department of Chemistry. Multiple advisory board members are University of Michigan faculty, and the company collaborates with Dr. Robert Bartlett's lab for ECMO and cardiac surgery applications.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage developer of nitric oxide delivery systems (LungFit) targeting respiratory infections and COPD. Directly comparable as a NO-generation platform company with hospital and home-use ambitions overlapping NOTA's NOGEN and LANOR systems.

TypeDirect peer
Description

Developer of GENOSYL, an FDA-approved tankless inhaled nitric oxide delivery system. Direct competitor in on-demand NO generation for hospital iNO therapy, targeting the same neonatal/PPHN and cardiac surgery markets as NOGEN.

TypeDirect peer
Description

Markets INOMAX, the FDA-approved standard-of-care inhaled nitric oxide therapy for neonatal PPHN and related indications. The entrenched incumbent in the iNO market that NOTA's cost-advantaged electrochemical system must displace.

TypeDirect peer
Description

Emerging developer of portable, on-demand nitric oxide generation technology for hospital and potentially home use. Directly comparable technology approach to NOTA's NOGEN and LANOR electrochemical/photochemical platforms.

5Bellerophon Therapeutics
TypeEmerging player
Description

Developed INOpulse, a pulsed inhaled nitric oxide delivery system for pulmonary hypertension and cardiopulmonary conditions. Comparable as a NO-delivery therapeutic developer, though its commercial trajectory has been constrained.

TypeBroad incumbent
Description

Global medtech leader whose heart-lung machines and ECMO systems are the platforms into which NOTA's NOGEN system would integrate during open heart surgery. Comparable as the dominant incumbent in the cardiac surgery device ecosystem NOTA targets.

TypeBroad incumbent
Description

Manufacturer of heart-lung machines, oxygenators, and ECMO systems used in cardiac surgery — the same procedural setting where NOGEN is positioned to deliver NO as a sweep gas. Broad incumbent in the cardiopulmonary bypass workflow.

TypeBroad incumbent
Description

Major manufacturer of intravascular catheters and catheter maintenance solutions, overlapping with NOTA's catheter lock solution for preventing CRBSI and thrombosis. Large incumbent with established hospital catheter relationships.

TypeBroad incumbent
Description

Manufacturer of IV catheters, catheter connectors, and needlefree connectors used in hospital infusion therapy. Comparable as an established player in the catheter care space where NOTA's NO-releasing lock solution competes.

TypeOthers
Description

Global medical gases supplier that, alongside Linde/Praxair, supplies tank-based nitric oxide to hospitals. Indirect competitor and potential partner as the industry transitions from tank-based delivery to on-demand generation systems like NOTA's.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NOTA Labs

Nitric Oxide Delivery Medical Devicesnotalabs.com

NOTA Labs is a University of Michigan spinout developing proprietary nitric oxide delivery systems (NOGEN electrochemical platform and LANOR UV-LED platform) plus a catheter lock solution for hospital, ambulatory, and home-care applications. Pre-commercial, investigational-use only.

What NOTA Labs does

NOTA Laboratories (doing business as NOTA Labs) is a University of Michigan spinout founded in 2014 and headquartered in Ann Arbor, Michigan. The company is a development-stage medical device firm focused on proprietary nitric oxide (NO) delivery systems that leverage NO's antiviral, antimicrobial, anti-inflammatory, anti-thrombotic, and vasodilatory properties. Products are explicitly for investigational use only and not available for commercial sale, with no disclosed revenue to date.

The company's core technology rests on two patented platform systems. NOGEN is an electrochemical system that generates high-volume nitric oxide (up to 500 ppm) continuously for up to 6 months by reducing nitrite, regulated by varying current and voltage with multi-sensor in-line controls; it targets hospital use cases including persistent pulmonary hypertension in newborns (PPHN), open-heart surgery (thrombosis and SIRS prevention), lung transplantation, and ECMO. LANOR is a UV-LED photochemical system that converts a solid NO donor molecule via light energy using a proprietary film cassette, producing a compact, lightweight, battery-operated device intended for home and ambulatory use, particularly for COPD patients. A catheter lock solution rounds out the pipeline. Single-use disposable NO technologies have been separated into a spinout, NOxygen Therapeutics.

NOTA's anticipated business model is hardware sales of the NOGEN and LANOR systems plus recurring consumable revenue from chemical cartridges and film cassettes, though no pricing has been disclosed. GTM is multi-modal: enterprise field sales targeting hospital systems for NOGEN, sales-led development partnerships with medical device distributors (notably the NGK/CAIRE joint development agreement for bundled oxygen-concentrator-plus-NO distribution into the COPD market), and a future direct-to-consumer motion for LANOR in home care. Capital structure includes a $4.3 million NIH SBIR grant and a second venture round led by Pegasus Tech Ventures.

NOTA Labs firmographics

Firmographics
Name
NOTA Labs
Legal name
NOTA Laboratories
Website
https://notalabs.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
NOTA Labs is a University of Michigan spinout developing proprietary nitric oxide delivery systems (NOGEN electrochemical platform and LANOR UV-LED platform) plus a catheter lock solution for hospital, ambulatory, and home-care applications. Pre-commercial, investigational-use only.
Ownership category
akta.pro rank

NOTA Labs industry classification

Industry
Product category
Nitric Oxide Delivery Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAGAD
Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHANAF
Personal Protective Equipment (PPE) (Gloves, Masks/Respirators, Gowns, Face Shields)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables

Keywords

  • Nitric oxide delivery
  • Medical device platforms
  • Inhaled nitric oxide therapy
  • Catheter lock solutions
  • Respiratory therapy devices

Where NOTA Labs is headquartered

Location

Headquarters

HQ city
Ann Arbor
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NOTA Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Hardware Sales: Pre-commercial development stage. Revenue anticipated from sale of NO generation systems (NOGEN and LANOR) along with associated disposable components (chemical cartridges, film cassettes). Products under development for FDA approval.

Go-to-market motion3 records

NOTA Labs product offering

Product offering

Core offering

NOTA Labs develops proprietary nitric oxide (NO) delivery platform technologies for therapeutic applications in respiratory, inflammatory, infectious, cardiovascular, and catheter-related conditions. The portfolio includes the NOGEN electrochemical system for high-volume hospital use, the LANOR UV-LED photochemical system for compact home/ambulatory use, and an NO-releasing intravascular catheter lock solution for infection and thrombosis prevention. All products are currently for investigational use only and not commercially available.

Product overview

NOTA Labs offers a portfolio of nitric oxide (NO) delivery systems comprising two platform technologies: the NOGEN System (electrochemical NO generation for hospital/high-volume applications) and the LANOR System (UV-LED photochemical NO generation for home/ambulatory use), along with a catheter lock solution for preventing catheter-related infections. All products leverage NO's antiviral, antimicrobial, anti-thrombotic, anti-inflammatory, and vasodilatory properties.

Differentiator

Problem solved

Functional benefit

Products and services

  • NOGEN System Electrochemical nitric oxide generation system that produces up to 500 ppm NO continuously for up to 6 months using inexpensive chemical cartridges; designed for hospital use in PPHN, open heart surgery (prevention of thrombosis and SIRS), lung transplantation, and ECMO/extracorporeal circulation applications. Products are for investigational use only and not commercially available.
  • LANOR System UV-LED based photochemical nitric oxide generation system that converts a solid NO donor molecule from a film cassette using light energy; compact, lightweight, and battery-operated, enabling home/ambulatory use for COPD, chronic respiratory infections, and emergency applications. Products are for investigational use only and not commercially available.
  • Catheter Lock Solution Novel nitric oxide-releasing intravascular (IV) catheter lock solution that delivers NO inside catheter walls to prevent microbial growth and clotting, reducing risk of catheter-related bloodstream infection (CRBSI) and catheter thrombosis for healthcare facilities.

Quantifiable outcome

  • NOGEN generates up to 500 ppm NO, compared to traditional tank-based systems costing $100/hour
  • +1 more outcomes

Companies that use NOTA Labs

Customer profile

Segments3 records

Ideal customer profiles3 records

NOTA Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

NOTA Labs partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • NGK Spark Plugs (Nagoya, Japan)coreStrategic or Co-development Partner · 28 September 2022NOTA signed a Joint Development Agreement with NGK Spark Plugs for development and manufacturing collaboration. NGK owns CAIRE Inc., a major supplier of oxygen concentrators for home, clinic, and hospital use. The collaboration aims to integrate NOTA's NO systems with CAIRE oxygen concentrators to provide broader solutions for COPD patients, potentially reducing exacerbations and improving quality of life. NGK brings expertise in design, engineering, and manufacturing to accelerate products to market.
  • University of MichigancoreStrategic or Co-development PartnerNOTA is a University of Michigan spinout company founded in 2014. The LANOR system was developed in collaboration with the University of Michigan. Dr. Mark Meyerhoff, the company's founder and chairman, leads research at the University's Department of Chemistry. Multiple advisory board members are University of Michigan faculty, and the company collaborates with Dr. Robert Bartlett's lab for ECMO and cardiac surgery applications.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

NOTA Labs competitors and assessment

Company assessment

Direct peers

  • Beyond Air: Commercial-stage developer of nitric oxide delivery systems (LungFit) targeting respiratory infections and COPD. Directly comparable as a NO-generation platform company with hospital and home-use ambitions overlapping NOTA's NOGEN and LANOR systems.
  • Vero Biotech: Developer of GENOSYL, an FDA-approved tankless inhaled nitric oxide delivery system. Direct competitor in on-demand NO generation for hospital iNO therapy, targeting the same neonatal/PPHN and cardiac surgery markets as NOGEN.
  • Mallinckrodt Pharmaceuticals: Markets INOMAX, the FDA-approved standard-of-care inhaled nitric oxide therapy for neonatal PPHN and related indications. The entrenched incumbent in the iNO market that NOTA's cost-advantaged electrochemical system must displace.
  • Third Pole Therapeutics: Emerging developer of portable, on-demand nitric oxide generation technology for hospital and potentially home use. Directly comparable technology approach to NOTA's NOGEN and LANOR electrochemical/photochemical platforms.

Emerging players

  • Bellerophon Therapeutics: Developed INOpulse, a pulsed inhaled nitric oxide delivery system for pulmonary hypertension and cardiopulmonary conditions. Comparable as a NO-delivery therapeutic developer, though its commercial trajectory has been constrained.

Broad incumbents

  • Medtronic: Global medtech leader whose heart-lung machines and ECMO systems are the platforms into which NOTA's NOGEN system would integrate during open heart surgery. Comparable as the dominant incumbent in the cardiac surgery device ecosystem NOTA targets.
  • Terumo: Manufacturer of heart-lung machines, oxygenators, and ECMO systems used in cardiac surgery — the same procedural setting where NOGEN is positioned to deliver NO as a sweep gas. Broad incumbent in the cardiopulmonary bypass workflow.
  • Becton, Dickinson and Company (BD): Major manufacturer of intravascular catheters and catheter maintenance solutions, overlapping with NOTA's catheter lock solution for preventing CRBSI and thrombosis. Large incumbent with established hospital catheter relationships.
  • ICU Medical: Manufacturer of IV catheters, catheter connectors, and needlefree connectors used in hospital infusion therapy. Comparable as an established player in the catheter care space where NOTA's NO-releasing lock solution competes.

Others

  • Air Liquide Healthcare: Global medical gases supplier that, alongside Linde/Praxair, supplies tank-based nitric oxide to hospitals. Indirect competitor and potential partner as the industry transitions from tank-based delivery to on-demand generation systems like NOTA's.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

NOTA Labs social profiles

Digital presence

NOTA Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NOTA Labs leadership team

Management profile

Number of profiles

Profiles8 records

NOTA Labs funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NOTA Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NOTA Labs

What does NOTA Labs do?

NOTA Labs develops proprietary nitric oxide (NO) delivery platform technologies for therapeutic applications in respiratory, inflammatory, infectious, cardiovascular, and catheter-related conditions. The portfolio includes the NOGEN electrochemical system for high-volume hospital use, the LANOR UV-LED photochemical system for compact home/ambulatory use, and an NO-releasing intravascular catheter lock solution for infection and thrombosis prevention. All products are currently for investigational use only and not commercially available.

Is NOTA Labs a public or private company?

NOTA Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was NOTA Labs founded?

NOTA Labs was founded in 2014. It employs 1 to 10 people.

Where is NOTA Labs based?

NOTA Labs is headquartered in Ann Arbor, United States, in the North America region.

How does NOTA Labs make money?

One revenue line is on record: medical Device Hardware Sales.

Who are NOTA Labs's main competitors?

Direct peers on record are Beyond Air, Vero Biotech, Mallinckrodt Pharmaceuticals and Third Pole Therapeutics. Bellerophon Therapeutics is listed as an emerging player. Broad incumbents are Medtronic, Terumo, Becton, Dickinson and Company (BD) and ICU Medical. Air Liquide Healthcare is listed as an others.

Does NOTA Labs have an API?

No public API is recorded for NOTA Labs.

What industry is NOTA Labs in?

NOTA Labs's product category is Nitric Oxide Delivery Medical Devices. Its primary akta.pro industry code is HLAHAGAD, Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC), with a secondary code of HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals